Global Lab Footprint ACM Global Laboratories operates in over 65 countries with wholly owned facilities in the U.S., U.K., India, and Singapore, enabling sponsors to run multinational trials with centralized testing and consistent quality.

Broad Testing Capabilities With more than 20 million tests annually across pathology, microbiology, molecular diagnostics, and toxicology, ACM supports diverse trial endpoints and biomarker analyses, reducing vendor fragmentation for sponsors.

Vaccine Expertise A track record of vaccine-related work including COVID-19 vaccine studies and infectious disease testing services positions ACM as a capable partner for vaccine trials and therapeutic development.

Growth through Expansions History of expanding capabilities via acquisitions and new service lines such as DrugScan integration and Smarter Testing for infectious disease signals a flexible, growth-oriented lab partner ready to align with sponsor needs.

Affiliation and Quality As an affiliate of Rochester Regional Health, ACM combines hospital-backed quality with central lab specialization, offering reliability, regulatory alignment, and access to broad clinical networks.